Cahill Financial Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
EP
Cahill Financial Advisors's ARKG Position: Q4 2021 in Review
Cahill Financial Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 1,395 shares — an estimated $104K sold.
Cahill Financial Advisors first reported a position in ARKG in Q3 2021 and held it in 1 quarter. The position peaked at $104K in Q3 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.
- Cahill Financial Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
- Cahill Financial Advisors sold 1,395 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $104K.
- Cahill Financial Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2021 and held it in 1 quarter.
- Cahill Financial Advisors's ARK Genomic Revolution ETF position peaked at $104K in Q3 2021.
- 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.
Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.